Augmentin Es-600 (Amoxicillin and Clavulanate Potassium)
Brand Names: Augmentin Es-600
Methodology & AI Transparency ⓘ
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Amoxicillin and Clavulanate Potassium (cross-referenced at /meds/amoxicillin-and-clavulanate-potassium) and registered by USAntibiotics, LLC, Augmentin Es-600 operates as a prescription brand-name penicillin-class antibacterial therapy (RxNorm RXN-B81964003; NDC 81964-003).
- 2 Real-world patient consensus: Commercial Augmentin Es-600 monograph (600 mg/5mL / 42.9 mg/5mL For Suspension) cross-indexed with generic Amoxicillin and Clavulanate Potassium for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $9.79 discount cash to $34.50 walk-in retail (NADAC $0.0179/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Augmentin Es-600 (Amoxicillin and Clavulanate Potassium)): nausea (3%), diarrhea (9%), vomiting (1%).
Ask our AI Specialists anything about Augmentin Es-600 (Amoxicillin and Clavulanate Potassium)
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Amoxicillin and Clavulanate Potassium (cross-referenced at /meds/amoxicillin-and-clavulanate-potassium) and registered by USAntibiotics, LLC, Augmentin Es-600 operates as a prescription brand-name penicillin-class antibacterial therapy (RxNorm RXN-B81964003; NDC 81964-003). Under 2025-10-14 FDA labeling for 600 mg/5mL / 42.9 mg/5mL For Suspension; 600 mg/5mL, Amoxicillin and clavulanate potassium tablets, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin.
Bioactive Amoxicillin and Clavulanate Potassium within Augmentin Es-600 governs penicillin-class antibacterial target modulation with class-characteristic hepatorenal disposition. Commercialized across 600 mg/5mL / 42.9 mg/5mL For Suspension; 600 mg/5mL (registered by USAntibiotics, LLC, SPL 2025-10-14), Augmentin Es-600 combines branded dosage-form consistency (NDC 81964-003) with transparent cash-pay comparisons spanning $9.79 to $34.50.
Pharmacokinetic profiling of Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) demonstrates an elimination half-life of Mean elimination half-life of 4 to 14 hours across adult Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) dosing with Oral fraction absorbed ranges from 58% to 70% (Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) 600) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of augmentin es-600 (amoxicillin and clavulanate potassium), reaching clinical onset within oral tmax achieved within 2 to 3 hours following augmentin es-600 (amoxicillin and clavulanate potassium) ingestion.
Titration schedules for Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) (600 mg/5mL / 42.9 mg/5mL For Suspension → 600 mg/5mL → 42.9 mg/5mL) require excluding previous anaphylactoid or exfoliative reaction attributed to augmentin es-600 (amoxicillin and clavulanate potassium); clinical scenarios where penicillin-class antibacterial exposure from augmentin es-600 (amoxicillin and clavulanate potassium) poses unacceptable risk; real-world patient logs highlight diarrhea (9% of reports), headache (5.5% of reports), dyspepsia (4.1% of reports) alongside a 87.00% Worth-It consensus.
Additive hyperkalemic or renal hemodynamic effects may emerge between Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) and RAAS therapy.
Verify medication reconciliation lists so Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) is not inadvertently duplicated with another penicillin-class antibacterial.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Augmentin Es-600 (Amoxicillin and Clavulanate Potassium)
- Clinical scenarios where penicillin-class antibacterial exposure from Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) poses unacceptable risk
Logged Side-Effect Incidence (21 Reports)
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Augmentin Es-600 (Amoxicillin and Clavulanate Potassium))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Bupropion as an augmenting agent in patients of depression with partial The percentage decrease of remitters was also significantly more in group B (60% as per HDRS score and 63% as per MADRS score), as compared to group A (24% as per HDRS score and 27% as per MADRS score) (p < 0.05), at the end... Basic & clinical pharmacology & toxicology • 2012-03-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 21895979 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparative Efficacy of Augmenting Escitalopram with Modified Electroconvulsive The positive impact of ESC with HF-rTMS on cognitive function was evidenced by improvements in all domines MoCA.Combining ESC with MECT or HF-rTMS exhibited enhanced effectiveness in alleviating depressive symptoms and... The Tohoku journal of experimental medicine • 2024-03-16 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 38171724 ↗ |
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0179/unit (~$0.54/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $9.79 / mo | View logs ↓ |
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) RxNorm Concept ID | RXN-B81964003 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0179 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.79 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Augmentin Es-600 (Amoxicillin and Clavulanate Potassium): FDA labeling (2025-10-14, NDC 81964-003), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Augmentin Es-600 (Amoxicillin and Clavulanate Potassium) community threads and patient logs by age, biological sex, dosage, and treatment duration.